Abstract
Introduction
The hematopoietic lineage-specific transcription factor PU.1 (encoded by Spi-1) is involved in the development of lymphoid and myeloid cells. Spi-1 knockout mice exhibit severe immunodeficiency with abolition of macrophages and B-cell production, and delayed production of neutrophils and T cells. Previous studies, including ours, have demonstrated that PU.1 plays critical roles in expression of several genes important for dendritic cell (DC) function, including H2-Ea (MHC class II, I-Eα) (1), Flt3 (2), Tnfsf4 (OX40L) (3), Cd80 and Cd86 (4) .
CD11c (encoded by Itgax) is a member of the β2 integrin family forming heterodimeric receptors with CD18 and is well known as a hallmark of DCs, because DCs constitutively express CD11c on the cell surface. Accordingly, it is known that ~5.3 kb of the Itgax promoter is used for DC-specific expression of a gene of interest in mice (5, 6) , even though CD11c expression is also detected to a lesser extent in some hematopoietic cells, such as NKs, macrophages, some activated B cells and T cells and hairy cell leukemia. Therefore, identification of transcription factors regulating Itgax gene expression will further facilitate our current understanding of the development of DCs.
Several studies have revealed the expression mechanism of human CD11c by using cell lines under a stimulated condition, by which inducible-activated and/or ubiquitously expressed transcription factors have been identified to regulate promoter function (7) (8) (9) (10) (11) (12) . Recently, we performed promoter analysis using mouse primary DCs aiming to reveal DC-specific gene regulation and revealed the AP-1 complex with JunD and Fra2 as a transcriptional activator of the Itgax promoter (13) . Considering that expression of JunD and Fra2 is observed in various cell types, the presence of another transcription factor(s) determining DC-specific expression of CD11c is expected. In the present study, we investigated the role of PU.1 in the regulation of the Itgax promoter using small interfering RNA (siRNA)-mediated gene knock down with promoter analysis and demonstrated that PU.1 transactivates the Itgax promoter via direct binding to the cis-element on the gene in DCs and through gene regulation of a partner molecule, IRF4, which transactivates the Itgax gene in a synergistic manner with PU.1.
Methods

Cells
Bone marrow-derived DCs (BMDCs) were generated from whole bone marrow cells of BALB/c mice (Japan SLC, Hamamatsu, Japan) as previously described (1) . All animal experiments were performed according to the approved guidelines of the Institutional Review Board of Tokyo University of Science and of Juntendo University School of Medicine, Tokyo, Japan. CD11c + BMDCs were isolated by using a MACS separation system with anti-mouse CD11c MicroBeads and an autoMACS (all from Miltenyi Biotech, Tubingen, Germany). LPS (1 µg ml −1 ; Sigma-Aldrich) was added into the culture medium to stimulate BMDCs. BM mast cells (BMMCs) were generated from BM cells by cultivation in the presence of 5 ng ml −1 of murine IL-3 (Peprotech) for >5 weeks. Cells of the simian kidney cell line CV-1 (RIKEN Cell Bank, Tsukuba, Japan) were maintained in DMEM (Sigma-Aldrich) supplemented with 10% fetal bovine serum and antibiotics, as described in our previous report (4) .
Knockdown by siRNA introduction
A 5 µl aliquot of 20 µmol l −1 Spi-1 siRNA (Stealth Select RNAi, Sfpi1-MSS247678, Invitrogen, Carlsbad, CA, USA), Irf4 siRNA (IRF4-MSS205500) or control siRNA (Stealth Negative Universal Control, Invitrogen) was introduced into 1 × 10 6 BMDCs using a Mouse Macrophage Nucleofector kit (Lonza, Basel, Switzerland) with a Nucleofector II (Lonza) set at Y-001.
Quantitative RT-PCR
cDNA was reverse transcribed from mRNA contained in the total RNA, which was prepared from BMDCs using an RNeasy kit (QIAGEN, Hilden, Germany) and a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA 
Luciferase assay
Reporter plasmids carrying a variety of 5′-deletions and a series of off-set mutations were generated in our previous study (13) . The expression plasmid, pCR-PU.1, which was also previously generated (14) , and its empty vector pCR3.1 (Invitrogen) were used for exogenous expression of PU.1 and for mock, respectively. CV-1 cells (1 × 10 6 ) were transfected with 500 ng of reporter plasmid, 100 ng of expression plasmid and 0.5 ng of pRL-null (Promega) by using FuGene6 (Roche Diagnostics, Indianapolis, IN, USA). Luciferase activity in cells harvested 20-24 h after transfection was measured as previously described (15) .
Electrophoretic mobility shift assay
EMSA was performed as previously described (16) . The probe was prepared by annealing 5′-FITC-labeled synthesized oligonucleotide of the following nucleotide sequence (Invitrogen) and 5′-FITC labeling its complementary oligonucleotide; 5′-CGCTGACAACTTCCCTCCTGGTCT-3′ (−66/−43 on the mouse Itgax gene). A TNT T7 Quick coupled transcription/translation system (Promega) was used to prepare the PU.1 protein using pCR-PU.1 as a template. Anti-PU.1 antibody (D-19, no. sc-5949; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and goat IgG (no. 02-6202, Invitrogen) were used.
ChIP assay
ChIP assay was performed as previously described (15) . Anti-PU.1 antibody and control goat IgG, which were also used for EMSA, were used. Anti-acetyl-histone H3 rabbit IgG (06-599, Upstate Biotechnology), anti acetyl-histone H4 rabbit IgG (06-866, Upstate Biotechnology) and control rabbit IgG (02-6102, Invitrogen) were also used. The amount of precipitated DNA was determined by quantitative PCR using an Applied Biosystems Step-One real-time PCR system. The nucleotide sequences of the primer sets for PCR were as follows: forward primer (5′-GGAACCAGAACAATATGTCACCAA-3′) and reverse primer (5′-GAGGCAGCCTACACACTTCCA-3′) to amplify the Itgax promoter (−171/−99).
Exogenous expression of PU.1
An expression plasmid pIRES2-AcGFP-3xFlag-mPU.1WT was generated by the insertion of a BglII/SalI fragment including the cDNA fragment encoding N-terminus 3×Flag-tagged mouse PU.1 prepared from p3×Flag-mPU.1 (3) into pIRES2-AcGFP (Clontech) digested with BglII and SalI (both in the multi-cloning site). Ten micrograms of the expression plasmid was introduced into 2 × 10 6 of BMMCs using a Neon 100 µl kit with a Neon transfection system (Invitrogen) set at Program #5. For the co-expression experiment, pCR3.1-PU.1 and pCR3.1-IRF4 (4) were used.
Statistical analysis
Statistical analysis was performed using a two-tailed Student's t-test with P values <0.05 considered to be significant.
Results and discussion
Introduction of Spi-1 siRNA reduces the expression of CD11c in DCs
To examine the involvement of PU.1 in the expression of CD11c in DCs, Spi-1 siRNA was introduced into BMDCs. First, we confirmed that the Spi-1 mRNA level in Spi-1 siRNAintroduced DCs was decreased to ~10% of that in control siRNA-introduced DCs, and that this reduction continued for at least from 48 to 96 h after siRNA transfection in an LPS stimulation-independent manner (Fig. 1A) . This result is in accord with that in our previous study (1) . The Itgax mRNA level in Spi-1 siRNA-introduced DCs was <60% of that in control cells at 48 h after transfection and further reduced at 72-96 h (Fig. 1B) . The mRNA levels of Spi-1 and Itgax were down-regulated by LPS stimulation (Fig. 1A and B) .
We also performed flow cytometry to determine the cell surface expression level of CD11c on siRNA-introduced cells. FACS analyses showed that Spi-1 knockdown by siRNA decreased the cell surface expression level of CD11c continuously until 96 h after siRNA transfection (Fig. 1C) .
These results indicate that PU.1 is involved in the transcription and subsequent protein expression of CD11c in DCs.
PU.1 transactivates the Itgax promoter
The Spi-1 siRNA experiment showed that knockdown of Spi-1 decreased the transcription of Itgax in BMDCs, suggesting that PU.1 functions as a transcriptional activator for the Itgax promoter. Therefore, to evaluate the effect of PU.1 on Itgax promoter activity, we performed reporter assays. The PU.1 expression plasmid was co-transfected with a series of reporter plasmids carrying various lengths of the Itgax promoter. Luciferase activity driven by the Itgax promoter −1085/+48 was up-regulated by enforced expression of exogenous PU.1. The up-regulating effect of co-expressed PU.1 on the luciferase activity was still observed when other reporter plasmids carrying shorter promoter regions, from −584/+48 to −80/+48, were used, whereas the luciferase activities of reporter plasmids possessing the −38/+48 site of the Itgax promoter and promoter-less construct (pGL3-Basic) were not affected by the co-expression of PU.1 ( Fig. 2A) . This result suggests that the Itgax promoter is transactivated by PU.1 through the cis-enhancing element likely located between −80 and −39 on the Itgax gene. Next, a series of mutant plasmids, in which off-set nucleotide replaces were introduced, were generated based on a reporter plasmid carrying the −120/+48 region of the Itgax promoter, to further identify the cis-enhancing element. Luciferase activities driven from mutants 1-5 that had nucleotide replacements between −113 and −78 were similarly increased by co-expression of PU.1, as was the case of the wild-type promoter (Fig. 2B) . This result is in agreement with the above-mentioned result suggesting that the cis-enhancing element is located between −80 and −39. Among mutants M6-M11, only mutant M9, whose nucleotide sequence at −56/−53 was changed from TTCC to AGAT, lacked the PU.1-dependent transactivation ability. These observations indicate that the Itgax promoter is transactivated by PU.1 through a typical Ets motif TTCC at −56/−53. The promoter activity of Itgax was markedly reduced by nucleotide replacement at −77/−66 (M6 and M7), whereas the transactivation ability responding to coexpressed PU.1 was retained. This site has been identified as a critical cis-element containing the AP-1-binding motif in our previous study and was essential for transcriptional activation of the Itgax promoter in a monocyte cell line and BMDCs (13) . Taken together, these results indicate that PU.1 and AP-1 transactivate the Itgax promoter through the Ets motif (−56/−53) and the AP-1-motif (−73/−67), respectively.
Binding of PU.1 to the cis-enhancing element in the Itgax promoter in vitro and in vivo
In order to clarify whether PU.1 directly binds to the Itgax promoter via −56/−53, EMSA was performed with the −66/−43 region as a probe. When the in vitro-translated PU.1 protein was mixed with FITC-labeled double-stranded probe DNA, a specific band shift appeared, which disappeared after the addition of the anti-PU.1 antibody but not the control antibody (Fig. 3A) . This result suggests that PU.1 directly binds to the −66/−43 region in vitro.
Next, we performed a ChIP assay to evaluate whether PU.1 binds to the Itgax promoter on chromosomal DNA in DCs expressing CD11c in vivo. The amount of chromosomal DNA containing the Itgax promoter region immunoprecipitated with anti-PU.1 antibody was significantly higher than that of control IgG, which was significantly decreased at 24 h after LPS stimulation (Fig. 3B) . The reduced binding level of PU.1 is coincident with the down-regulation of mRNA levels of Spi-1 and Itgax in LPS-stimulated BMDCs (Fig. 1A and B) . When a ChIP assay was performed at 1 h after stimulation, acetylation of histone H3 and H4 was markedly suppressed, whereas a significant difference was not observed in the degree of PU.1 binding (Fig. 3C) . Taken together, these results indicate that PU.1 binds to the Itgax promoter in BMDCs under a steadystate condition, which is reduced by LPS stimulation following rapid suppression of histone acetylation, resulting in downregulation of the Itgax mRNA level.
Exogenous expression of PU.1 induces the cell surface expression of CD11c
We then evaluated the effect of PU.1 on the expression of CD11c by transfecting BMMCs, whose PU.1 expression level is lower than that of DCs, with an expression plasmid directing production of GFP with PU.1. As shown in Fig. 3(D) , the apparent amount of CD11c molecule was detected on a cell surface of a GFP + population of BMMCs transfected with PU.1-expressing plasmid, whereas such expression was not observed in mock transfectants and a GFP − fraction of the PU.1 transfectant. These data indicate that exogenously enforced expression of PU.1 induces CD11c expression on primarily CD11c − cells.
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Role of IRF4 in the CD11c expression PU.1 functions as a monomer and as a heterodimer with the partner molecule IRF4 or IRF8 (17, 18) . Irf4-and Irf8-deficient mice showed reduction of specific subpopulations of DCs (19, 20) , suggesting the possibility that IRF4 and/or IRF8 are also involved in CD11c expression. To investigate the role of PU.1 and IRFs in the expression of IRFs and CD11c, respectively, we determined mRNA levels of these molecules in each siRNA-introduced BMDCs. The Irf4 mRNA level was decreased in Spi-1-knocked down BMDCs (Fig. 4A) , and knockdown of Irf4 reduced the mRNA level (Fig. 4B ) and cell surface expression of CD11c (Fig. 4C ), whereas the Irf8 expression level was not affected by Spi-1 knockdown (data not shown). Furthermore, enforced expression of exogenous PU.1 and IRF4 increased the Itgax mRNA level by ~4.4-fold and 7.5-fold, respectively, and co-expression of both PU.1 and IRF4 dramatically up-regulated the Itgax mRNA level by 114-fold (Fig. 4D ). These results demonstrate that PU.1 is also involved in the CD11c expression as a positive regulator of gene expression of a partner molecule, IRF4, which subsequently transactivates the Itgax gene in a synergistic manner with PU.1. Previous studies in Spi-1-deficient mice demonstrated a critical role for PU.1 in the development of macrophages, B cells, T cells, DCs, NK cells and neutrophils (21) (22) (23) (24) (25) (26) . Detection of CD11c expression in PU.1-positive cells may support the conclusion that PU.1 is critical for cell-type specific expression of CD11c. A cis-enhancing element, TTCC, at −56/−53, which was identified as the PU.1 binding site in the present study, contains a typical Ets motif, but not an EICE sequence that is required for binding with a heterodimer PU.1/IRF4. Therefore, IRF4 may regulate Itgax expression via other region(s) on the gene, although the specific binding of IRF4 on the Itgax gene has not been detected in our preliminary experiment, probably due to the problem of specificity and/or affinity of the anti-IRF4 antibodies. In publicly available ChIP-seq data, there is an additional stronger PU.1 binding signal in the 8th intron (~4 kb downstream from transcription start site, in Fig. 4E) . Therefore, the identified 5′ region may not be the sole mechanism by which PU.1 induces the gene expression of Itgax, although the Itgax promoter works in the transgenic mice, in which a gene of interest is expressed in a DC-specific manner. Considering that this site in the coding region contains Ets motifs but not an EICE, PU.1 probably binds this region as a monomer. Regardless, further detailed analysis is required to reveal the mechanism of IRF4-mediated CD11c expression.
PU.1 plays an important role as a master regulator of gene expression and development of DCs. Against several genes including Flt3, Cd80, Cd86 and Tnfsf4 (2-4), PU.1 transactivates the target genes via direct binding to the regulatory elements on the gene. In the case of MHC class II, the role of PU.1 is indirect. Briefly, PU.1 activates the first promoter of the cofactor Ciita gene, which subsequently induces gene expression of H2-Ea (MHC class II, I-Eα) in DCs (1) . In the present study, it was found that PU.1 is involved in the expression of its own partner molecule IRF4. Although the knockdown of Spi-1, but not Irf4, affects expression levels of CIITA and MHC class II (1), PU.1 and IRF4 exhibit a synergistic role in CD11c expression.
Several studies have demonstrated that the expression level of PU.1 determines hematopoietic cell fate, including between B cells and macrophages (27) , neutrophils and macrophages (28) , and mast cells and monocytes (29, 30) . Furthermore, commitment of subtypes between conventional DCs (cDCs) and plasmacytoid DCs (pDCs) is also dependent on the PU.1 concentration. Briefly, a high concentration of PU.1 accelerates development toward cDCs and suppresses pDC development (2) . The expression level of CD11c, a higher level in cDCs and a lower level in pDCs, may reflect the PU.1 concentration. Elucidation of the mechanisms that regulate the amount of PU.1 protein in cells is required to understand PU.1-mediated development of hematopoietic cells. 
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